A phase I/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet/triplet chemotherapy: results of the phase I study. (February 2017) - Ross, P.J.; Repana, D.; Saunders, M.; Wilson, R.H.; Plummer, C.J.; Summers, J.; Higgins, F.; Peacock, J.; Harari, D.; Bridgewater, J.